Literature DB >> 3373555

In vivo amplification and rearrangement of c-myc oncogene in human breast tumors.

M Bonilla1, M Ramirez, J Lopez-Cueto, P Gariglio.   

Abstract

We have studied the genomic organization of cellular myc (c-myc) proto-oncogene in 48 human primary breast tumors. Two types of alterations (amplification and rearrangement) were observed in 27 (56%) of the tumors studied. The c-myc proto-oncogene appeared to be amplified 2- to 15-fold in the DNA of 20 tumors (41%). Non-germ line c-myc-related fragments (rearrangements) of variable size were detected in 7 primary breast tumors (6 malignant, 1 benign); 4 of these tumors presented both rearrangement and amplification, and the other 3 presented rearrangement only. The majority of the tumors analyzed were invasive ductal adenocarcinomas; 58% of these showed c-myc locus genetic alterations. Although the c-myc alterations described here do not appear to correlate with the aggressive behavior of primary breast tumors, they seem to be associated with development of breast carcinoma.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373555     DOI: 10.1093/jnci/80.9.665

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  15 in total

1.  Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival.

Authors:  A N Jain; K Chin; A L Børresen-Dale; B K Erikstein; P Eynstein Lonning; R Kaaresen; J W Gray
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

2.  C-myc as a predictive marker for chemotherapy in metastatic breast cancer.

Authors:  Nataša Todorović-Raković; Zora Nešković-Konstantinović; Dragica Nikolić-Vukosavljević
Journal:  Clin Exp Med       Date:  2011-11-24       Impact factor: 3.984

3.  The prognostic value of tumor-associated carbohydrate structures correlated with gene amplifications in human breast carcinomas.

Authors:  T Fukutomi; S Hirohashi; H Tsuda; T Nanasawa; H Yamamoto; M Itabashi; Y Shimosato
Journal:  Jpn J Surg       Date:  1991-09

4.  Amplification and overexpression of the L-MYC proto-oncogene in ovarian carcinomas.

Authors:  Rong Wu; Lin Lin; David G Beer; Lora H Ellenson; Barbara J Lamb; Jean-Marie Rouillard; Rork Kuick; Samir Hanash; Donald R Schwartz; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.

Authors:  M A Sovak; R E Bellas; D W Kim; G J Zanieski; A E Rogers; A M Traish; G E Sonenshein
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

6.  Ha-ras rare alleles in breast cancer susceptibility.

Authors:  K Conway; S Edmiston; D B Fried; B S Hulka; P A Garrett; E T Liu
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

Review 7.  Genetic alterations in primary breast cancer.

Authors:  R Callahan
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

8.  Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies.

Authors:  G D Lewis; I Figari; B Fendly; W L Wong; P Carter; C Gorman; H M Shepard
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

9.  Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element.

Authors:  Joshua P Frederick; Nicole T Liberati; David S Waddell; Yigong Shi; Xiao-Fan Wang
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

10.  Isolation and structural analysis of a 1.2-megabase N-myc amplicon from a human neuroblastoma.

Authors:  S S Schneider; J L Hiemstra; B A Zehnbauer; P Taillon-Miller; D L Le Paslier; B Vogelstein; G M Brodeur
Journal:  Mol Cell Biol       Date:  1992-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.